Prolonged Extubation in Gastric Cancer With OSA

Shandong University

Status: Invitation-only

Conditions: Gastric Cancer (GC); Obstructive Sleep Apnea

Treatments: Procedure: Prolonging the duration of postoperative endotracheal intubation before extubation.

Study type: Observational

Funder types: Other

Identifiers

NCT07362706

KYLL-202110-034-2

Details and patient eligibility

About

This study aims to investigate the effect of prolonged tracheal intubation removal on the incidenceof postoperative complications in patients with gastric cancer complicated with severe obstructive sleepapnea.

Full description

This study retrospectively included patients who underwent radical gastrectomycombined with severe obstructive sleep apnea at Qilu Hospital . Accordingto the assessment of anesthesiologists, whether the anesthetic drugs of the patients were adequatelymetabolized during the operation. The patients were divided into two groups, the extended tracheal intubationremoval time group (24-48h)and the non-extended tracheal intubation removal time group, and the incidenceof surgery-related complications and non-surgical-related complications in the two groups werecompared.

Enrollment: 240 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients preoperatively diagnosed with resectable gastric cancer
2. Patients without distant organ metastasis
3. Patients with preoperative Overnight Cardiorespiratory Sleep Testing (OCST) or Polysomnography (PSG) results showing Apnea-Hypopnea Index (AHI) >30 events/hour and SaO₂ <80%
4. Patients with cardiopulmonary function deemed suitable for surgery
5. Patients aged 18-85 years
6. Patients who voluntarily joined this study and provided written informed consent

Exclusion criteria

1. Patients with a history of or concurrent other malignant tumors
2. Patients who underwent palliative resection
3. Subjects who experienced acute cardiovascular or cerebrovascular events (e.g., acute cerebral infarction, acute coronary syndrome) within the past 3 months, or whose cardiovascular clinical symptoms/diseases are not well-controlled
4. Patients with a history of psychotropic drug abuse that cannot be abstained, or those with psychiatric disorders
5. Patients with concomitant diseases that, in the investigator's judgment, seriously endanger the patient's safety or affect the completion of the study

Trial design